Regina Berkovich, MD, PhD

June 22, 2022

A trio of experts in multiple sclerosis exchanges their thoughts on the use of the sphingosine-1 phosphate modulating class of medicines in treating the disease. [WATCH TIME: 3 minutes]

June 22, 2022

A trio of experts in multiple sclerosis exchanges their thoughts on the gains that have been made in the understanding of the progressive phases of the disease. [WATCH TIME: 3 minutes]

June 22, 2022

A trio of experts in multiple sclerosis exchanges their thoughts on the importance of patient-reported outcomes in the management of patients with the disease. [WATCH TIME: 3 minutes]

June 17, 2022

Expert neurologists comment on the impact of COVID-19 on telemedicine and MS treatment selection.

June 10, 2022

Dr Regina Berkovich evaluates the use of mRNA COVID-19 vaccines in patients treated with high efficacy disease-modifying therapies for MS.

June 10, 2022

Barry A. Hendin, MD, reviews guidance on COVID-19 vaccines for patients with MS, including highlights from the AAN position statement.

June 03, 2022

Drs Barry A. Hendin and Regina Berkovich comment on the management and treatment of chronic smoldering inflammation with high efficacy therapies.

June 03, 2022

Regina Berkovich, MD, PhD, and Barry A. Hendin, MD, review clinical implications of real-world data on the use of cladribine and other DMTs in patients with relapsing MS that were presented at ACTRIMS 2022.

May 27, 2022

Expert neurologists discuss factors guiding their choice of high-efficacy therapy in multiple sclerosis.

May 27, 2022

Regina Berkovich, MD, PhD, shares her approach to selecting high-efficacy therapies in clinical practice for patients with multiple sclerosis.